Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01REE
|
|||
| Former ID |
DIB003839
|
|||
| Drug Name |
DA-3031
|
|||
| Synonyms |
Long-acting agent (neutropenia), Dong-A; PEG-GCSF (neutropenia), Dong-A; PEG-granulocyte colony stimulating factor (neutropenia),Dong-A
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Neutropenia [ICD-11: 4B00.0; ICD-9: 288] | Phase 3 | [1] | |
| Company |
Dong-A Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H19NO2
|
|||
| Canonical SMILES |
CC(=C)C(=O)OCCN(C)C.C=C
|
|||
| InChI |
1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
|
|||
| InChIKey |
PNMYDOBPCBCQIA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 25134-54-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor (CSF3) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Malaria | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| TNFalpha Signaling Pathway | ||||
| TCR Signaling Pathway | ||||
| WikiPathways | Cytokines and Inflammatory Response | |||
| Hematopoietic Stem Cell Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01674855) Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia. U.S. National Institutes of Health. | |||
| REF 2 | A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6. | |||
| REF 3 | Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. Clin Drug Investig. 2013 Nov;33(11):817-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.